y*****l
发帖数: 5997 | 1 Who want talk about it's drug? May have a run soon.
http://finviz.com/screener.ashx?v=341&t=ISIS
Thursday, May 05, 2011 at 4:30 p.m. ET / 1:30 p.m. PT ER & CC
http://finance.yahoo.com/news/Isis-Pharmaceuticals-to-prnews-39
http://finance.yahoo.com/news/Regulus-Therapeutics-and-bw-79616
Isis Pharmaceuticals to Present at the 14th Annual Bank of America Merrill
Lynch Health Care Conference
2 hours 59 minutes ago - PR Newswire Europe via Comtex
PR Newswire EuropeIsis Pharmaceuticals, Inc. , the leader in antisense
therapeutics, today announced that management will present a company
overview at Bank of America Merrill Lynch's 14th Annual Health Care
Conference on Tuesday, May 10, 2011 at 1:40 p.m. PT at the Encore at the
Wynn in Las Vegas.
A live audio webcast of the presentation will be available on the "Investors
& Media" section of the Company's Web site, www.isispharm.com. A replay of
the presentation will be available on the Isis Web site within 48 hours and
will be archived for a limited time.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop novel drugs
for its product pipeline and for its partners. The Company has successfully
commercialized the world's first antisense drug and has 24 drugs in
development. Isis' drug development programs are focused on treating
cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.
Isis' partners are developing antisense drugs invented by Isis to treat a
wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners
of Regulus Therapeutics Inc., a company focused on the discovery,
development and commercialization of microRNA therapeutics. Isis also has
made significant innovations beyond human therapeutics resulting in products
that other companies, including Abbott, are commercializing. As an
innovator in RNA-based drug discovery and development, Isis has designed and
executed a patent strategy that has provided the Company with strong and
extensive protection for Isis' drugs and technology. Additional information
about Isis is available at www.isispharm.com.
CONTACT: Kristina Lemonidis, Director, Corporate
Communications,+1-760-603-2490, Amy Blackley, Ph.D., Assistant Director,
CorporateCommunications, +1-760-603-2772, both of Isis Pharmaceuticals
Web site: http://www.isispharm.com/ |
|
